Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors

Due to improved understanding of the role of bone morphogenetic protein 4 (BMP4) in an increasing number of diseases, the development of selective inhibitors of BMP4 is an attractive therapeutic option. The currently available BMP4 inhibitors are not suitable as therapeutics because of their low spe...

Descripción completa

Detalles Bibliográficos
Autores principales: Calpe, Silvia, Correia, Ana C. P., Sancho-Serra, Maria del Carmen, Krishnadath, Kausilia K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966848/
https://www.ncbi.nlm.nih.gov/pubmed/26967714
http://dx.doi.org/10.1080/19420862.2016.1158380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966848/
https://www.ncbi.nlm.nih.gov/pubmed/26967714
http://dx.doi.org/10.1080/19420862.2016.1158380

Ejemplares similares